Adnan I Qureshi1, Morad Chughtai1, Elhadj Ibrahima Bah2, Moumié Barry3, Kézély Béavogui4, Tokpagnan Oscar Loua5, Ahmed A Malik1. 1. Zeenat Qureshi Stroke Institute, St. Cloud Minnesota; 2. Department of Infectious and Parasitic Diseases, Donka National Hospital, Conakry, Guinea; 3. Chief, Department of Infectious and Parasitic Diseases and Head of Victims of Ebola Hemorrhagic Fever Virus, Donka National Hospital, Conakry, Guinea; 4. Chief Medical Officer, Department of Neurosurgery, Donka National Hospital, Conakry, Guinea and National Program to Combat Trauma and Violence in Guinea, Ministry of Health and WHO, Guinea; 5. Department of Neurosurgery, Donka National Hospital, Conakry, Guinea.
Abstract
BACKGROUND: Anecdotal reports suggesting that survival rates among hospitalized patients with Ebola virus disease in Guinea are higher than the 29.2% rate observed in the current epidemic in West Africa. METHODS: Survival after symptom onset was determined using Kaplan Meier survival methods among patients with confirmed Ebola virus disease treated in Conakry, Guinea from March 25, 2014, to August 5, 2014. We analyzed the relationship between survival and patient factors, including demographics and clinical features. RESULTS: Of the 70 patients analyzed [mean age ± standard deviation (SD), 34 ± 14.1; 44 were men], 42 were discharged alive with a survival rate among hospitalized patients of 60% (95% confidence interval, 41.5-78.5%). The survival rate was 28 (71.8%) among 39 patients under 34 years of age, and 14 (46.7%) among 30 patients aged 35 years or greater (p = 0.034). The rates of myalgia (3 of 42 versus 7 of 28, p = 0.036) and hiccups (1 of 42 versus 5 of 28, p = 0.023) were significantly lower among patients who survived. CONCLUSIONS: Our results provide insights into a cohort of hospitalized patients with Ebola virus disease in whom survival is prominently higher than seen in other cohorts of hospitalized patients.
BACKGROUND: Anecdotal reports suggesting that survival rates among hospitalized patients with Ebola virus disease in Guinea are higher than the 29.2% rate observed in the current epidemic in West Africa. METHODS: Survival after symptom onset was determined using Kaplan Meier survival methods among patients with confirmed Ebola virus disease treated in Conakry, Guinea from March 25, 2014, to August 5, 2014. We analyzed the relationship between survival and patient factors, including demographics and clinical features. RESULTS: Of the 70 patients analyzed [mean age ± standard deviation (SD), 34 ± 14.1; 44 were men], 42 were discharged alive with a survival rate among hospitalized patients of 60% (95% confidence interval, 41.5-78.5%). The survival rate was 28 (71.8%) among 39 patients under 34 years of age, and 14 (46.7%) among 30 patients aged 35 years or greater (p = 0.034). The rates of myalgia (3 of 42 versus 7 of 28, p = 0.036) and hiccups (1 of 42 versus 5 of 28, p = 0.023) were significantly lower among patients who survived. CONCLUSIONS: Our results provide insights into a cohort of hospitalized patients with Ebola virus disease in whom survival is prominently higher than seen in other cohorts of hospitalized patients.
Authors: S Baize; E M Leroy; A J Georges; M-C Georges-Courbot; M Capron; I Bedjabaga; J Lansoud-Soukate; E Mavoungou Journal: Clin Exp Immunol Date: 2002-04 Impact factor: 4.330
Authors: John S Schieffelin; Jeffrey G Shaffer; Augustine Goba; Michael Gbakie; Stephen K Gire; Andres Colubri; Rachel S G Sealfon; Lansana Kanneh; Alex Moigboi; Mambu Momoh; Mohammed Fullah; Lina M Moses; Bethany L Brown; Kristian G Andersen; Sarah Winnicki; Stephen F Schaffner; Daniel J Park; Nathan L Yozwiak; Pan-Pan Jiang; David Kargbo; Simbirie Jalloh; Mbalu Fonnie; Vandi Sinnah; Issa French; Alice Kovoma; Fatima K Kamara; Veronica Tucker; Edwin Konuwa; Josephine Sellu; Ibrahim Mustapha; Momoh Foday; Mohamed Yillah; Franklyn Kanneh; Sidiki Saffa; James L B Massally; Matt L Boisen; Luis M Branco; Mohamed A Vandi; Donald S Grant; Christian Happi; Sahr M Gevao; Thomas E Fletcher; Robert A Fowler; Daniel G Bausch; Pardis C Sabeti; S Humarr Khan; Robert F Garry Journal: N Engl J Med Date: 2014-10-29 Impact factor: 91.245
Authors: M A Bwaka; M J Bonnet; P Calain; R Colebunders; A De Roo; Y Guimard; K R Katwiki; K Kibadi; M A Kipasa; K J Kuvula; B B Mapanda; M Massamba; K D Mupapa; J J Muyembe-Tamfum; E Ndaberey; C J Peters; P E Rollin; E Van den Enden; E Van den Enden Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: A M Rojek; A Salam; R J Ragotte; E Liddiard; A Elhussain; A Carlqvist; M Butler; N Kayem; L Castle; L 'o Odondi; K Stepniewska; P W Horby Journal: Clin Microbiol Infect Date: 2019-07-05 Impact factor: 8.067
Authors: Jake Dunning; Foday Sahr; Amanda Rojek; Fiona Gannon; Gail Carson; Baimba Idriss; Thomas Massaquoi; Regina Gandi; Sebatu Joseph; Hassan K Osman; Timothy J G Brooks; Andrew J H Simpson; Ian Goodfellow; Lucy Thorne; Armando Arias; Laura Merson; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Benjamin Hope-Gill; Mauricio Ferri; Jennifer Grove; Mark Kowalski; Kasia Stepniewska; Trudie Lang; John Whitehead; Piero Olliaro; Mohammed Samai; Peter W Horby Journal: PLoS Med Date: 2016-04-19 Impact factor: 11.069
Authors: Jake Dunning; Stephen B Kennedy; Annick Antierens; John Whitehead; Iza Ciglenecki; Gail Carson; Rupa Kanapathipillai; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Jennifer Grove; Janet Scott; Trudie Lang; Piero Olliaro; Peter W Horby Journal: PLoS One Date: 2016-09-09 Impact factor: 3.240